. Am J Kidney Dis 2008, 52:531?40. six. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality threat for dialysis individuals with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52:519?30. 7. Goodman WG: Health-related management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003, 18:2?. 8. Ihle B, Becker G, Kincaid-Smith P: Clinical and biochemical characteristics of aluminium-related bone illness. Kidney Int 1986, 29:S80 86. 9. Block G, Uribarri J, Coladonato JA, Fan SL, Cunningham J, Nolan CR, Qunibi WY, Lindberg JS: How need to hyperphosphatemia be managed in dialysis patients? Semin Dial 2002, 15(5):315?28. 10. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478?483. 11. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate inside the remedy of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999, 33:694?01.12. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999, 55:299?07. 13. Brezina B, Qunibi WY, Nolan CR: Acid loading for the duration of treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl 2004, 9(90):S39 45. 14. Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J: Long-term comparison of a calcium-free phosphate binder and calcium carbonate ?phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004, 62:104?15. 15. Locatelli F, D’Amico M, Pontoriero G: Lanthanum carbonate. Drugs 2003, six:688?95. 16. Behets GJ, Verberckmoes SC, D’Haese Computer, de Broe ME: Lanthanum carbonate: a brand new phosphate binder. Curr Opin Nephrol Hypertens 2004, 13:403?09. 17. Finn WF, Joy MS, Hladik GA, And the Lanthanum Study Group: Efficacy and security of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure getting hemodialysis.Fmoc-Ser-OtBu Chemscene Clin Nephrol 2004, 62:193?01.BuyOclacitinib Maleate 18.PMID:33627038 Hutchison AJ, Speake M, Al Baaj F: Decreasing higher phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dosefinding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004, 19:1902?906. 19. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG: Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011, 16:290?98. 20. Haese Pc, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, de Broe ME: A multicenter study around the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone illness in dialysis sufferers. Kidney Int Suppl 2003, 6(85):S73 78. 21. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC: SPD405-307 Lanthanum Carbonate Study Group: Impr.